The product, called Viaskin, showed it could help allergic children aged four to seven who wore it for a year, the French company said Tuesday. The patients then consumed peanut protein to mimic an accidental ingestion, and researchers found they could tolerate it better. DBV said it plans to seek US regulatory approval in the first half of next year.
DBV shares surged as much as 47% in Paris on Wednesday morning before paring gains to ...